Transmucosal drug delivery: prospects, challenges, advances, and future directions.

Expert opinion on drug delivery Pub Date : 2025-04-01 Epub Date: 2025-02-25 DOI:10.1080/17425247.2025.2470224
Francis Brako, Joshua Boateng
{"title":"Transmucosal drug delivery: prospects, challenges, advances, and future directions.","authors":"Francis Brako, Joshua Boateng","doi":"10.1080/17425247.2025.2470224","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Traditional administration routes have limitations including first-pass metabolism and gastrointestinal degradation for sensitive drugs (oral) and pain associated with parenteral injections, which also require trained personnel and refrigeration, making them expensive. This has increased interest in alternative routes, with mucosal surfaces being of high priority.</p><p><strong>Areas covered: </strong>Mucosal routes include ocular, oral (buccal/sublingual), nasal and vaginal mucosae which avoid the limitations of the oral and parenteral routes. Though mucosal routes show great potential, they are still hindered by several barriers, especially for systemic absorption, resulting in the development of more advanced novel drug delivery systems to overcome these limitations and achieve therapeutic actions both locally and systemically, similar to or exceeding the oral route. This paper systematically reviews and compares the different mucosal routes, challenges, and recent advances in advanced novel drug delivery system design for emerging clinical challenges including the advent of large biological macromolecules (proteins, peptides, and RNA) for treatment and prevention of diseases. The review also focuses on current challenges and future perspectives.</p><p><strong>Expert opinion: </strong>Among the various transmucosal routes discussed, nose-to-brain drug delivery has the greatest translational potential to go beyond the current state of the art and achieve significant clinical impact for neurological diseases.</p>","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"525-553"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on drug delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17425247.2025.2470224","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/25 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Traditional administration routes have limitations including first-pass metabolism and gastrointestinal degradation for sensitive drugs (oral) and pain associated with parenteral injections, which also require trained personnel and refrigeration, making them expensive. This has increased interest in alternative routes, with mucosal surfaces being of high priority.

Areas covered: Mucosal routes include ocular, oral (buccal/sublingual), nasal and vaginal mucosae which avoid the limitations of the oral and parenteral routes. Though mucosal routes show great potential, they are still hindered by several barriers, especially for systemic absorption, resulting in the development of more advanced novel drug delivery systems to overcome these limitations and achieve therapeutic actions both locally and systemically, similar to or exceeding the oral route. This paper systematically reviews and compares the different mucosal routes, challenges, and recent advances in advanced novel drug delivery system design for emerging clinical challenges including the advent of large biological macromolecules (proteins, peptides, and RNA) for treatment and prevention of diseases. The review also focuses on current challenges and future perspectives.

Expert opinion: Among the various transmucosal routes discussed, nose-to-brain drug delivery has the greatest translational potential to go beyond the current state of the art and achieve significant clinical impact for neurological diseases.

导言:传统给药途径有其局限性,包括敏感药物的首过代谢和胃肠道降解(口服)以及肠外注射带来的疼痛,肠外注射还需要训练有素的人员和冷藏设备,因此费用昂贵。因此,人们对其他途径的兴趣日益浓厚,其中粘膜表面给药是优先考虑的途径:粘膜途径包括眼部、口腔(颊/舌下)、鼻腔和阴道粘膜,可避免口腔和肠外途径的局限性。虽然粘膜给药途径显示出巨大的潜力,但它们仍然受到一些障碍的阻碍,尤其是在全身吸收方面,因此需要开发更先进的新型给药系统来克服这些限制,以实现局部和全身的治疗作用,类似或超过口服途径。这篇综述系统地回顾和比较了不同的粘膜途径、先进新型给药系统设计的挑战和最新进展,以应对新出现的临床挑战,包括用于治疗和预防疾病的大型生物大分子(蛋白质、肽和 RNA)的出现。本综述还重点介绍了当前面临的挑战和未来展望:在所讨论的各种经粘膜给药途径中,鼻脑给药途径具有最大的转化潜力,可超越目前的技术水平并产生重大临床影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信